CASE REPORTS   MICROBIOLOGY

Fabrizio Cialente, et al.: Running title

Laryngeal tuberculosis in renal transplant recipients: A case report and review of the literature

Fabrizio Cialente¹, Michele Grasso¹, Massimo Ralli¹, Marco de Vincentiis², Antonio Minni¹, Griselda Agolli¹, Michele Dello Spedale Venti³, Mara Riminucci³, Alessandro Corsi³, Antonio Greco¹

¹Department of Sense Organs, Sapienza University of Rome, Rome, Italy
²Department of Oral and Maxillofacial Sciences, Sapienza University of Rome, Rome, Italy
³Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy

*Corresponding author: Michele Grasso, Department of Sense Organs, Sapienza University of Rome, Viale del Policlinico, 155, Rome 00186, Italy. Phone: +39 06 4997 6804. E-mail: michele.grasso@uniroma1.it

DOI: https://dx.doi.org/10.17305/bjbms.2020.4448

Submitted: 09 September 2019/Accepted: 20 February 2020

Conflict of interest statement: The authors declare no conflict of interests

 Licence: © The Author(s) (2020). This work is licensed under a Creative Commons Attribution 4.0 International License
ABSTRACT

Renal allograft recipients are at greater risk of developing tuberculosis than the general population. A woman with a kidney transplant was admitted to the emergency department with high temperature, dysphonia, odynophagia, and asthenia. The final diagnosis was laryngeal tuberculosis. Multidisciplinary collaboration enabled accurate diagnosis and successful treatment. Laryngeal tuberculosis should be considered in renal allograft recipients with hoarseness. A more rapid diagnosis of tuberculosis in renal transplant recipients is desirable when the site involved, such as the larynx, exhibits specific manifestations and the patient exhibits specific symptoms. In these cases, prognosis is excellent, and with adequate treatment, a complete recovery is often achieved.

KEYWORDS: Laryngeal tuberculosis; kidney transplant; laryngeal leukoplakia
INTRODUCTION

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis [1]. Geographically, most TB cases in 2018 were in Southeast Asia (44%), Africa (24%), and the Western Pacific nations (18%); smaller numbers of cases have occurred in eastern Mediterranean nations (8%), the Americas (3%), and Europe (3%) [1]. In 2018, the number of new cases of rifampicin-resistant TB was approximately half a million, of which 78% were multidrug-resistant TB [1]. Although the prevalence of TB is low in Italy, its epidemiology is changing. Since 1955, more than 160,000 people in Italy have died from this potentially preventable and curable disease [10]. In 2018, the estimated incidence of TB in Italy was 4300 new cases (7 cases per 100,000 population), and the estimated number of deaths from TB in Italy was 370. The number of TB case notifications in 2018 in Italy was 3912 (71% with pulmonary involvement) [1].

Although the lung is the most common site of involvement, a number of extrapulmonary organs, including the larynx, can be involved as well. Laryngeal TB is an uncommon condition and has been rarely reported in the literature [1,2]. Nevertheless, it represents a public health concern [3] and may appear similar to malignancy on imaging and laryngoscopy [4,5].

Renal allograft recipients are at greater risk of developing tuberculosis (TB), commonly atypical and extrapulmonary, than is the general population. The prevalence of TB in renal transplant recipients ranges from 1% to 4% in developed Western countries [6-9].

We present the case of a kidney transplant recipient who developed laryngeal TB. This case represents a rare condition.

CASE REPORT

A 38-year-old woman with chronic renal failure caused by chronic diabetes mellitus from the age of 9 was admitted to the emergency department of the Sapienza University Hospital, Rome, Italy, in December 2018 with high temperature, dysphonia, odynophagia, general discomfort, and severe asthenia. She reported having undergone a thoracotomy with right-sided pneumectomy at the age of 16 for previous pulmonary aspergillosis and renal transplantation in 2015 at the age of 35 and
subsequent treatment with steroids, mycophenolate mofetil, and tacrolimus. Laryngeal and pulmonary mycosis were initially suspected, and she was transferred to the Department of Infectious Diseases and treated with antimycotic drugs. A neck and pulmonary computed tomographic (CT) scan showed asymmetry of the glottic space with marked contrast enhancement of the epiglottis up to the false right vocal fold; submucosal imbibition up to the thyroid cartilage, which appeared to be inhomogeneous with pseudo-focality; and right-sided level II lymphadenopathy with a maximum lymph node diameter of 12 mm. We also found right-sided lung atelectasis with ipsilateral mediastinal displacement (as a result of the earlier thoracotomy with right pneumectomy) and hyperplasia of the left lung with interstitial thickening. Otolaryngologic examination with high-definition fiber optic laryngoscopy (Figure 1) showed swelling of the right false vocal fold with a whitish lesion; motility and respiratory space were normal. Endoscopy of the larynx with narrow-band imaging confirmed that the lesion was not malignant.

The patient underwent microlaryngoscopy under general anesthesia, and a biopsy sample of the whitish lesion was obtained. Histologic examination (Figure 2) revealed that the mucosa was lined by respiratory epithelium free from atypia. Lymphocyte-rich inflammatory infiltrates, along with multiple small, nonnecrotizing granulomatous aggregates of epithelioid histiocytes (CD68R+), were detected in the lamina propria. Ziehl-Neelsen and periodic acid–Schiff staining did not yield conclusive findings. Subsequent microbiologic bronchoalveolar lavage and sputum tests confirmed the diagnosis of pulmonary TB with extrapulmonary laryngeal extension. The patient was then isolated for 30 days and treated daily with 200 mg of isoniazid, 400 mg of ethambutol, 500 mg of pyrazinamide, 400 mg of moxifloxacin, and 300 mg of vitamin B6 (Benadon). As of this writing, the patient is not isolated and undergoes regular follow-up visits with clinical examinations and CT scans every 2 months.
DISCUSSION

Renal transplant recipients at high risk for different infections because they must receive immunosuppressive therapy [11]. Using the keywords “laryngeal TB” and “kidney transplant,” we searched PubMed for articles written in English from 1990 and on about the occurrence of laryngeal TB in kidney transplant recipients. Inclusion criteria were kidney transplantation and laryngeal TB, and we included only articles in which laryngeal involvement occurred before or at the same time as pulmonary involvement. We reviewed five reports about a total of eight patients [9-10,12-13]. In these cases, laryngeal symptoms were prominent (dysphonia, hoarseness) and directed the diagnosis. We excluded one article in which the authors diagnosed laryngeal TB after the occurrence of pulmonary TB (in a patient with cavitary pulmonary TB who was found to have laryngeal TB 1 year after discontinuing antituberculous drugs) [6]. In our review, we evaluated the following parameters: clinical manifestations, results of diagnostic tests, and treatment. In these patients (Table 1), the main symptoms were hoarseness, dysphonia, odynophagia, cough, and fever, and biopsy samples of tissue revealed granulomatous inflammation. The treatment of TB may be complex, and drug resistance often develops [14,15]. Standard therapeutic agents include isoniazid, rifampicin, and pyrazinamide, although modifications of therapy because of cost have been reported in the literature [10]; neither of the patients were given rifampicin because it would have necessitated an increase in the cyclosporine dose and, consequently, the cost of therapy. Since laryngeal TB in renal transplant recipients is an atypical presentation of TB, the diagnosis may be delayed, which can lead to increased morbidity and exposure of the patients’ contacts, particularly through nosocomial transmission. The mechanism of laryngeal involvement is postulated to be through bronchogenic spread, with infected sputum from the lungs directly contaminating the larynx. However, this theory has been challenged by other authors [9], who suggested that hematogenous spread is responsible for laryngeal seeding.

Immunosuppressive drugs promote reactivation of latent TB and acquisition of new disease. In many studies [10-12], the main symptoms that forced patients to seek medical attention were severe
fever and severe odynophagia, although patients had already had other symptoms, such as dysphonia and asthenia, for weeks. The differential diagnosis must include laryngeal TB. Larynx assessment with advanced endoscopy and narrow-band imaging enables diagnosis [16]. We used endoscopes capable of narrow-band imaging to rule out suspected malignant lesions of the larynx because our institution is a referral center for the treatment of laryngeal cancer in Italy. Whitish lesions of larynx could occur in many types of diseases, ranging from benign hyperkeratosis to squamous cell carcinoma. Other clinical conditions included in the differential diagnosis are sarcoidosis, Wegener’s granulomatosis, syphilis, histoplasmosis, blastomycosis, coccidioidomycosis, cryptococcosis, amyloidosis, traumatic polypoid granulation, and laryngeal papilloma [16-18]. Thus, biopsy may be performed for differential diagnostic purpose.

In two cases in the literature, standard treatment was isoniazid, rifampicin, and pyrazinamide, although both patients required threefold increases in the daily cyclosporine dosage to maintain therapeutic levels. Because of the drug interaction between rifampicin and cyclosporine, the dosage of cyclosporine must be increased substantially when it is coadministered with rifampicin [19, 20]. The results of both randomized and nonrandomized studies support the value of isoniazid as TB prophylaxis in renal transplant recipients at risk for active infection [21]. Clinicians should consider prophylaxis in renal transplant recipients in endemic areas or in recipients in nonendemic countries who are at risk. We treated our patient with isoniazid because she was at risk for active infection, according to the literature [22-25]. However, the evidence of the benefit of isoniazid prophylaxis in renal transplantation is not robust, and a large multicenter trial is needed to investigate isoniazid prophylaxis in kidney transplantation in an endemic area [26].

Laryngeal TB is rare in kidney transplant recipients who developed TB. The few cases reported in the literature indicate that laryngeal symptoms (dysphonia, dysphagia) in such patients must be assessed adequately, even in industrialized countries in which TB is not widespread. In these cases, prognosis is excellent and recovery is often achieved. When whitish lesions are found in the larynx, diagnostic tests for TB must be performed.
CONCLUSION

Laryngeal TB should be considered in renal allograft recipients with hoarseness. A more rapid diagnosis of TB in renal transplant recipients is desirable when the site involved, such as the larynx, exhibits specific manifestations and the patient exhibits specific symptoms. In these cases, prognosis is excellent, and with adequate treatment, a complete recovery is often achieved.
REFERENCES

1. Global tuberculosis report 2019. https://www.who.int/tb/publications/global_report/en/

2. Kurokawa M, Nibu K, Ichimura K, Nishino H. Laryngeal tuberculosis: A report of 17 cases. Auris Nasus Larynx. 2015;42(4):305–310.

3. Zavod MB. Laryngeal tuberculosis: A public health concern. Ear Nose Throat J. 2015;94(10-11):E51–E52.

4. El Kettani NE, El Hassani M, Chakir N, et al. Primary laryngeal tuberculosis mimicking laryngeal carcinoma: CT scan features. Indian J Radiol Imaging 2010;20(1):11–12.

5. Suhail A, Ahmed MS, Sobani ZU, Ghaffar S. Laryngeal tuberculosis presenting as laryngeal carcinoma. J Pak Med Assoc. 2012;62(2):167–168.

6. Yildiz A, Sever MS, Türkmen A, Ecder T, Beşişik F, Tabak L, Ece T, Kiliçarslan I, Ark E. Tuberculosis after renal transplantation: experience of one Turkish centre. Nephrol Dial Transplant. 1998;13(7):1872–1875.

7. Conversano M. Update on the epidemiology of tuberculosis in Italy. J Rheumatol Suppl. 2014;91:4–10. doi: 10.3899/jrheum.140096

8. Rosado Rubio, C., et al., Atypical localization of tuberculosis in kidney transplants. Nefrologia. 2011;31(5): 622–624.

9. Lui, S.L., et al., Tuberculous infection in southern Chinese renal transplant recipients. Clin Transplant. 2004;18(6):666–671.

10. Jha, V., et al., Laryngeal tuberculosis in renal transplant recipients. Transplantation, 1999. 68(1): p. 153-5.

11. Lim MA, Kohli J, Bloom RD. Immunosuppression for kidney transplantation: Where are we now and where are we going?. Transplant Rev (Orlando). 2017;31(1):10–17.

12. Tato, A.M., et al., Laryngeal tuberculosis in renal allograft patients. Am J Kidney Dis. 1998;31(4):701–705.
13. Poniachik, J., et al., Tuberculosis in kidney transplant patients. Rev Med Chil. 1990;118(10):1105–1110.
14. Hunter, A.M., et al., The changing pattern of laryngeal tuberculosis. J Laryngol Otol. 1981;95(4):393–398.
15. Wang M, Wei H, Zhao Y, et al. Analysis of multidrug-resistant bacteria in 3223 patients with hospital-acquired infections (HAI) from a tertiary general hospital in China. Bosn J Basic Med Sci. 2019;19(1):86–93.
16. Kimza, H., Jackowska, J., and Wierzbicka, M. The usefulness of the NBI - narrow band imaging for the larynx assessment. Otolaryngol Pol. 2018;72(3):1–3.
17. Parker, N.P., Vocal fold leukoplakia: incidence, management, and prevention. Curr Opin Otolaryngol Head Neck Surg. 2017;25(6):464–468.
18. Fang, T.J., et al., Classification of vocal fold leukoplakia by clinical scoring. Head Neck. 2016;38 Suppl 1:E1998–E2003.
19. Vachharajani, T., et al., Diagnosis and treatment of tuberculosis in hemodialysis and renal transplant patients. Am J Nephrol. 2000;20(4):273–277.
20. Campana, C., et al., Clinically significant drug interactions with cyclosporin. An update. Clin Pharmacokinet. 1996;30(2):141–179.
21. Naqvi R, Naqvi A, Akhtar S, Ahmed E, Noor H, Saeed T, Akhtar F, Rizvi A. Use of isoniazid chemoprophylaxis in renal transplant recipients. Nephrol Dial Transplant. 2010;25(2):634–637.
22. Higgins RM, Cahn AP, Porter D, Richardson AJ, Mitchel RJ, Hopkin JM, Morris PJ. Mycobacterial infections after renal transplantation. Q J Med 1991;78:145–153.
23. EBPG. Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.7.2. Late infections. Tuberculosis. Nephrol Dial Transplant. 2002;17(Suppl 4):39–43.
24. John GT, Thomas PP, Thomas M, Jeyaseelan L, Jacob CK, Shastry JC. A double-blind randomized controlled trial of primary isoniazid prophylaxis in dialysis and transplant patients. Transplantation 1994;57:1683.

25. Vachharajani T, Abreo K, Phadke A, Oza U, Kirpalani A. Diagnosis and treatment of tuberculosis in hemodialysis and renal transplant patients. Am J Nephrol. 2000;20:273.

26. Currie, A.C., Knight, S.R., and Morris, P.J. Tuberculosis in renal transplant recipients: the evidence for prophylaxis. Transplantation. 2010;90(7):695–704.
FIGURES AND TABLES

FIGURE 1. Laryngoscopic images. (A) Before antitubercular therapy. Swelling of the right false vocal fold with a whitish lesion, normal motility, and respiratory space. (B). After antitubercular therapy. Normal motility and structure of larynx, with normal respiratory space.

FIGURE 2. Eosin and hematoxylin staining of the sampled mucosa under low- (A) and high-power (B) magnification illustrates the lymphocyte-rich inflammatory infiltrates along with multiple small, nonnecrotizing granulomas (arrows in A and B). The immunohistochemical stain for CD68R (C) highlights the small granulomatous aggregates of histiocytes. Bars represent 100 µm in A and 50 µm in B and C.
| Subject of study                                      | No. of patients | Clinical manifestation          | Diagnostic tests                                                                                      | Treatment                                                                 |
|-------------------------------------------------------|-----------------|---------------------------------|--------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Laryngeal tuberculosis in renal transplant recipients [6] | 2               | Prolonged hoarseness and painful dysphagia | Histological study of laryngeal biopsy sample revealed large numbers of inflammatory cells, scattered epithelioid cells, and histiocytes along with a few multinucleated giant cells and a few areas of necrosis. Ziehl-Nielsen staining was strongly positive for acid-fast bacilli. | No different from tuberculosis elsewhere. Neither patient was given rifampicin because it would have necessitated an increase in the cyclosporine dose and, consequently, the cost of therapy |
| Laryngeal tuberculosis in renal allograft recipients [7] | 2               | 2-week febrile illness with hoarseness and dysphagia | Direct laryngoscopy and sputum results were positive for acid-fast bacilli that subsequently grew *Mycobacterium tuberculosis* | Isoniazid, rifampicin, and pyrazinamide in each case; both patients required threefold increases in daily cyclosporine dosage to maintain therapeutic levels. |
| Atypical localization of tuberculosis in kidney transplant recipients [4] | 1               | Dysphonia with whitish lesions on arytenoid cartilage and epiglottis | Direct laryngoscopy with laryngeal biopsy revealed tuberculoid granulomatous chronic laryngitis. Ziehl-Neelsen staining and Löwenstein test yielded positive results. Acid-fast | Isoniazid, rifampicin, and pyrazinamide for 2 months and isoniazid and rifampicin for 9 months |
| Tuberculous infection in southern Chinese renal transplant recipients [5] | 2 | Hoarseness of voice, fever, cough | Direct laryngoscopy with laryngeal biopsy, test of sputum, bronchoalveolar lavage, and chest radiography were performed. Laryngeal biopsy revealed typical caseating granulomata and acid-fast bacilli | Both patients received isoniazid, 300 mg/day; rifampicin, 450–600 mg/day; and pyrazinamide, 1.5–2 g/day. Pyrazinamide was stopped after 3 months |
|------------------------|---|-----------------------------|-------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|
| Tuberculosis in kidney transplant recipients [8] | 1 | Fever, dysphonia | Direct laryngoscopy with laryngeal biopsy demonstrated acid-fast bacilli in sputum |  |